Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
5-aminolevulinic acid hydrochloride + CV01
- Development stage
- Unknown
- Lead developer
- Universität Münster
- Modality
- Light/Condition-Responsive Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Administration
- Oral
01
Overview
5-aminolevulinic acid hydrochloride (5-ALA HCl), known by the brand name Gliolan, is a small molecule prodrug utilized in sonodynamic therapy (SDT) for the treatment of high-grade gliomas. Administered orally, 5-ALA is preferentially metabolized within tumor cells into protoporphyrin IX (PpIX), a potent sonosensitizer. In a clinical protocol evaluated by Universität Münster, the CV01 ultrasound device is used to deliver low-intensity ultrasound to the tumor site, triggering PpIX to produce reactive oxygen species (ROS) that induce localized cell death (apoptosis). This drug-device combination is primarily investigated as a neoadjuvant treatment administered prior to surgical resection to target malignant cells in newly diagnosed patients with glioblastoma or other high-grade gliomas.
- Brand names
- Gliolan
- Other names
- 5-ALA HCl5-aminolevulinic acid hydrochlorideSonodynamic therapy
Beyond the preview
Go deeper on 5-aminolevulinic acid hydrochloride + CV01.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 5-aminolevulinic acid hydrochloride + CV01.